The approval EYLEA for macular edema following CRVO was based on data from the Phase III studies Copernicus and Galileo. In both studies, the primary endpoint was the proportion of patients with at least 15 letters ETDRS best corrected visual acuity at 24 weeks was won compared to baseline on the ETDRS visual acuity chart. Copernicus and Galileo per month group was better than the control group for the primary endpoint. Results from week 24 to 52 of Copernicus and Galileo, studies have not yet been evaluated by the FDA.
Bayer HealthCare s cooperation partner Regeneron Pharmaceuticals announced today that the U.S. Food and Drug Administration EYLEA has Injection, known in the scientific literature as VEGF Trap-Eye, approved for treatment of macular edema following central retinal vein Occlusion .To C compared to the burden to the subjection to 25 C but it felt Identify the viscoelasticity of ACV -A. ACV A did a larger tolerance to emphasize, and a higher viscosity and yield stress as the other two cremes. Results of the sensory test shown are significant differences in the adhesiveness, spreadability, Y. Supporter on ACV Pat as compared to W – ACV and ACV – C. So the viscosity and the elasticity difference because of different type cremes and relations additives were noted. Those differences thought in order to be disparities in physical characteristics. ‘.. Notice news journalists obtain a quotation from research by Josai University, ‘Near – infra spectroscopy showed changes at absorption spectrums reflecting differences in of oil and water content the 3 creams Moreover ACV – B and.